LifeStance Health Group (NASDAQ:LFST) Major Shareholder Tpg Gp A, Llc Sells 13,643,207 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the sale, the insider directly owned 98,101,407 shares in the company, valued at $1,041,836,942.34. This represents a 12.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

LifeStance Health Group Stock Up 6.3%

LFST stock opened at $12.23 on Thursday. The company’s 50 day moving average price is $10.19 and its 200 day moving average price is $8.16. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 94.08 and a beta of 1.14. LifeStance Health Group, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $12.43. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.01) EPS. On average, equities research analysts anticipate that LifeStance Health Group, Inc. will post 0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC grew its holdings in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after buying an additional 3,791 shares during the last quarter. KBC Group NV purchased a new stake in LifeStance Health Group during the 1st quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its stake in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after acquiring an additional 5,404 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in LifeStance Health Group during the 2nd quarter worth approximately $52,000. Finally, PNC Financial Services Group Inc. lifted its position in LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after acquiring an additional 7,987 shares during the period. 85.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LFST has been the subject of a number of research reports. KeyCorp boosted their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. The Goldman Sachs Group began coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.62.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst support remains strong. Morgan Stanley reaffirmed its Buy rating, while BTIG Research recently raised its price target from $15 to $16 and maintained a Buy rating. These actions reinforce the bullish view of LifeStance’s growth prospects. Morgan Stanley Reaffirms Their Buy Rating on LifeStance Health Group
• Positive Sentiment: LifeStance’s earnings momentum is supporting the stock. The company recently exceeded quarterly earnings and revenue expectations, with revenue rising 26.1% year over year. Zacks also upgraded LFST to a Rank #2 (Buy), citing improving earnings prospects. LifeStance Health Upgraded to Buy
• Positive Sentiment: Investor interest has pushed LFST to a new 52-week high. The move reflects strong recent momentum and growing optimism about the company’s fundamentals, although the elevated valuation increases the importance of continued execution. LifeStance Health Group Sets New 1-Year High
• Neutral Sentiment: LifeStance released survey findings highlighting demand for mental-health services integrated into perimenopause and menopause care. The announcement supports awareness of a potential growth niche but does not directly change financial guidance. LifeStance Survey on Menopause Care
• Negative Sentiment: Several insiders reduced their holdings. Major shareholder TPG GP A sold 13.64 million shares for approximately $144.9 million, while the COO and CTO sold shares worth about $519,845 and $481,675, respectively. Although each seller retained a substantial position, the transactions may raise concerns about profit-taking and near-term selling pressure. LifeStance Insider Sale Filing

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.